Prostate cancer screening: Current status and future perspectives

Nature Reviews Urology

Volumn 7, Issue 9, 2010, Pages 487-493

  Strope, Seth A ^a   Andriole, Gerald L ^a  

^a USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TUMOR MARKER;

CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; HIGH RISK PATIENT; HUMAN; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

FORECASTING; HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77956511576     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2010.120     Document Type: Review

References (59)

1. Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
2. Holmberg, L. et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N. Engl. J. Med. 347, 781-789 (2002).
3. Farkas, A., Schneider, D., Perrotti, M., Cummings, K. B. & Ward, W. S. National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 52, 444-448 (1998).
4. Welch, H. G. & Albertsen, P C. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 19862005. J. Natl Cancer Inst. 101, 1325-1329 (2009).
5. Kvale, R. et al. interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J. Natl Cancer Inst. 99, 1881-1887 (2007).
6. Shao, Y. H. et al. Contemporary risk profile of prostate cancer in the United States. J. Natl Cancer Inst. 101, 1280-1283 (2009).
7. Moore, A. L. et al. Population-based prostate- specific antigen testing in the UK leads to a stage migration of prostate cancer. BJU Int. 104, 1592-1598 (2009).
8. Kopec, J. A. et al. Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study. J. Urol. 174, 495-499 (2005).
9. Etzioni, R., Gulati, R., Falcon, S. & Penson, D. F. impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med. Decis. Making 28, 323-331 (2008).
10. Draisma, G. et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J. Natl Cancer Inst. 95, 868-878 (2003).
11. Kondylis, F. i., Moriarty, R. P, Bostwick, D. & Schellhammer, P F. Prostate cancer grade assignment: the effect of chronological, interpretive and translation bias. J. Urol. 170, 1189-1193 (2003).
12. Albertsen, P C. et al. Prostate cancer and the Will Rogers phenomenon. J. Natl Cancer Inst. 97, 1248-1253 (2005).
13. Wolters, T. et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int. J. Cancer 126, 2387-2393 (2010).
14. Horner, M. J. et al. Table 23.1: cancer of the prostate (invasive). Surveillance Epidemiology and End Results [online], http:// seer.cancer.gov/csr/ 1975 2006/ results single/sect 23 table.01.pdf (2009).
15. Collin, S. M. et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol. 9, 445-452 (2008).
16. Agalliu, i., Weiss, N. S., Lin, D. W. & Stanford, J. L. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men. Cancer Causes Control 18, 931-937 (2007).
17. Bartsch, G. et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 58, 417-424 (2001).
18. Bartsch, G. et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int. 101, 809-816 (2008).
19. Etzioni, R. et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control 19, 175-181 (2008).
20. Etzioni, R. & Feuer, E. Studies of prostate- cancer mortality: caution advised. Lancet Oncol. 9, 407-409 (2008).
21. Concato, J. et al. The effectiveness of screening for prostate cancer: a nested case- control study. Arch. Intern. Med. 166, 38-43 (2006).
22. Shibata, A., Ma, J. & Whittemore, A. S. Prostate cancer incidence and mortality in the United States and the United Kingdom. J. Natl Cancer Inst. 90, 1230-1231 (1998).
23. Oliver, S. E., Gunnell, D. & Donovan, J. L. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 355, 1788-1789 (2000).
24. Shaw, P A. et al. An ecologic study of prostate- specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am. J. Epidemiol. 160, 1059-1069 (2004).
25. Lu-Yao, G. et al. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 325, 740 (2002).
26. Barry, M. J. The PSA conundrum. Arch. Intern. Med. 166, 7-8 (2006).
27. Albertsen, P C., Hanley, J. A. & Fine, J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293, 2095-2101 (2005). (Pubitemid 40617061)
28. Carroll, P et al. Prostate-specific antigen best practice statement: 2009 update. American UrologicalAssociation [online], . auanet.org/content/media/ psa09.pdf (2009).
29. Abrahamsson, P A., Artibani, W., Chapple, C. R. & Wirth, M. European Association of Urology position statement on screening for prostate cancer. Eur. Urol. 56, 270-271 (2009).
30. ito, K., Kakehi, Y, Naito, S. & Okuyama, A. Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan. Int. J. Urol. 15, 763-768 (2008).
31. Smith, R. A., Cokkinides, v., Brooks, D., Saslow, D. & Brawley, O. W. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J. Clin. 60, 99-119 (2010).
32. Lim, L. S. & Sherin, K. Screening for prostate cancer in U. S. men: ACPM position statement on preventive practice. Am. J. Prev. Med. 34, 164-170 (2008).
33. National Health Service. Prostate Cancer Risk Management Programme [online], http://www.cancerscreening.nhs.uk/prostate/index.html (2010).
34. Lin, K., Lipsitz, R., Miller, T. & Janakiraman, S. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the, U. S. Preventive Services Task Force. Ann. Intern. Med. 149, 192-199 (2008).
35. Prorok, P C. et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control. Clin. Trials 21 (6 Suppl.), 273S-309S (2000).
36. Grubb, R. L. iii et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int. 102, 1524-1530 (2008).
37. Pinsky, P F. et al. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J. Urol. 173, 746-750 (2005).
38. Andriole, G. L. et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310-1319 (2009).
39. Schroder, F. H. et al. Screening and prostate- cancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320-1328 (2009).
40. Roobol, M. J., Grenabo, A., Schroder, F. H. & Hugosson, J. interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J. Natl Cancer Inst. 99, 1296-1303 (2007).
41. Albertsen, P C. Efficacy vs effectiveness in prostate-specific antigen screening. J. Natl Cancer Inst. 102, 288-289 (2010).
42. Wever, E. M. et al. Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam. J. Natl Cancer Inst. 102, 352-355 (2010).
43. Bill-Axelson, A. et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J. Natl Cancer Inst. 100, 1144-1154 (2008).
44. Widmark, A. et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase iii trial. Lancet 373, 301-308 (2009).
45. Stephenson, A. J. et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J. Clin. Oncol. 27, 4300-4305 (2009).
46. Thompson, i. M. et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294, 66-70 (2005).
47. Thompson, i. M. et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215-224 (2003).
48. Thompson, i. M. et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J. Natl Cancer Inst. 98, 1128-1133 (2006).
49. Andriole, G. L. et al. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 362, 1192-1202 (2010).
50. Andriole, G. et al. The effect of dutasteride on the utility of PSA for the diagnosis of high-grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J. Urol. (in press).
51. Ploussard, G. & de la Taille, A. Urine biomarkers in prostate cancer. Nat. Rev. Urol. 7, 101-109 (2000).
52. Wang, R., Chinnaiyan, A. M., Dunn, R. L., Wojno, K. J. & Wei, J. T. Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer 115, 3879-3886 (2009).
53. Zheng, S. L. et al. Cumulative association of five genetic variants with prostate cancer. N. Engl. J. Med. 358, 910-919 (2008).
54. Gelmann, E. P Complexities of prostate-cancer risk. N. Engl. J. Med. 358, 961-963 (2008).
55. Lilja, H. et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J. Clin. Oncol. 25, 431-436 (2007).
56. Loeb, S. et al. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 67, 316-320 (2006).
57. Ulmert, D. et al. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med. 6, 6 (2008).
58. Fang, J. et al. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 58, 411-416 (2001).
59. Draisma, G. et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J. Natl Cancer Inst. 101, 374-383 (2009).